Capula Management’s 10x Genomics TXG Stock Holding History

Capula Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-44,971	Closed	-$1.02M	–	605
2024 Q3	$1.02M	Buy	+44,971	New	+$930K	0.01%	123

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capula Management's TXG Position: Q4 2024 in Review

Capula Management sold out of 10x Genomics (TXG) in Q4 2024, closing a stake of 44,971 shares — an estimated $1.02M sold.

Capula Management first reported a position in TXG in Q3 2024 and held it in 1 quarter. The position peaked at $1.02M in Q3 2024. 273 funds tracked by Wall St. Rank hold TXG as of Q4 2024.

Capula Management reported no remaining 10x Genomics position as of Q4 2024 after selling out during the quarter.
Capula Management sold 44,971 10x Genomics shares in Q4 2024, an estimated $1.02M.
Capula Management first reported a position in 10x Genomics in Q3 2024 and held it in 1 quarter.
Capula Management's 10x Genomics position peaked at $1.02M in Q3 2024.
273 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2024.

Based on Capula Management's 13F filing for Q4 2024, filed 13 Feb 2025.